TWO WEEKS TO DECISION ON FATE OF DEUTSCH'S LOST PFIZER ACCOUNTS

Zyrtec, Zoloft and Bextra May Get Full Creative Reviews

By Published on .

NEW YORK (AdAge.com) -- Pharmaceutical company Pfizer will have its brand managers for Zyrtec, Zoloft and Bextra decide whether those accounts will go into a full creative review or simply shift to another shop, agency executives close to the situation said.

The three prescription drugs were

Related Stories:
PFIZER AND DEUTSCH SPLIT
Contract Stalemate Cited
previously handled by Interpublic Group of Cos.' Deutsch, New York. But the agency and Pfizer had a disagreement over the drug company's requests for information during the renegotiation of compensation agreements, and the two parted ways last week.

The brand managers are expected to make a decision within the next two weeks, the executives said.

The allergy drug Zyrtec and the antidepressant Zoloft represent more than $120 million in ad spending by Pfizer, according to Taylor Nelson Sofres' CMR.

In this article:
Most Popular